X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Elaine Herrmann Blais of Goodwin Procter.Elaine Herrmann Blais of Goodwin Procter. (Courtesy photo)

A 2010 law that created a fast track for approving biosimilar drugs just got a boost toward the U.S. Supreme Court. In early December, the solicitor general recommended that the high court review the Biologics Price Competition and Innovation Act (BPCIA). The 2010 law established a complex series of disclosures, known as the patent dance, between branded biologic drugmakers and companies that want to market less expensive biosimilar versions. We asked Goodwin Procter partner Elaine Herrmann Blais, editor of the firm’s Big Molecule Watch blog, for an update.

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.